Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.68 |
| ▸ | XDH | P47989 | 3/20 | 0.62 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | POLA1 | P09884 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27738783 | 0.98 | GDA (0.66) | GDAXDHPNPPOLA1 | |
| Hydrochloric Acid SCHEMBL27339405 | 0.98 | GDA (0.66) | GDAXDHPNPPOLA1 | |
| Thiophene SCHEMBL27638389 | 0.90 | GDA (0.57) | GDAXDH | |
| SCHEMBL10597950 | 0.83 | GDA (0.64) | GDAXDHPNPPOLA1 | |
| SCHEMBL28183797 | 0.83 | GDA (0.50) | GDAXDHPOLA1 | |
| SCHEMBL19466100 | 0.83 | GDA (0.76) | GDAXDHPNPPOLA1 | |
| SCHEMBL852109 | 0.83 | GDA (0.63) | GDAXDHPNPPOLA1 | |
| SCHEMBL8886042 | 0.83 | GDA (0.63) | GDAXDHPNPPOLA1 | |
| SCHEMBL29407603 | 0.83 | GDA (0.63) | GDAXDHPNPPOLA1 | |
| SCHEMBL1843779 | 0.83 | GDA (0.63) | GDAXDHPNPPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5524 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| WO-2026099790-A1 | DEVICE USING ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-05-15 | — | — | WO | claimed |
| US-20260131157-A1 | METHODS OF USING ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-05-14 | — | — | US | claimed |
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| WO-2026088246-A1 | METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT COMPOUND | ＮＴＴ株式会社 | 2026-04-30 | — | — | WO | claimed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4663187-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | Laminar Pharmaceuticals, S.A. (ES) | 2025-12-17 | — | — | EP | claimed |
| CN-1451759-A | Methylation state of liver cancer related gene promoter CpG island and use thereof | SHANGHAI ONCOLOGY INST (CN) | 2003-10-29 | — | — | CN | claimed |
| WO-2003072600-A2 | METHODS OF SCREENING MOLECULAR LIBRARIES FOR ACTIVE MOLECULES THAT RESTORE THE FUNCTION OF TARGET PROTEINS AND PEPTIDES THAT RESTORE THE FUNCTION OF MUTANT P53 | GARDNER, REBECCA, KATHERINE (GB) | 2003-09-04 | — | — | WO | claimed |
| CN-1345328-A | Cleaving the nucleotides from the solid support | ANDREW GOLDSBOROUGH (FR) | 2002-04-17 | — | — | CN | claimed |
| EP-1165585-A1 | CLEAVAGE OF NUCLEIC ACID FROM SOLID SUPPORTS | Goldsborough, Andrew (FR) | 2002-01-02 | — | — | EP | claimed |
| WO-2000058329-A1 | CLEAVAGE OF NUCLEIC ACID FROM SOLID SUPPORTS | GOLDSBOROUGH, ANDREW (FR) | 2000-10-05 | — | — | WO | claimed |
| WO-1999025386-A1 | delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-05-27 | — | — | WO | claimed |
| EP-0540693-B1 | THE REDUCTION OF NON-SPECIFIC AMPLIFICATION DURING $i(IN VITRO) NUCLEIC ACID AMPLIFICATION USING MODIFIED NUCLEIC ACID BASES | HOFFMANN LA ROCHE (CH) | 1999-01-20 | — | — | EP | claimed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | claimed |
| EP-0540693-A1 | THE REDUCTION OF NON-SPECIFIC AMPLIFICATION DURING $i(IN VITRO) NUCLEIC ACID AMPLIFICATION USING MODIFIED NUCLEIC ACID BASES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001814-A2 | THE REDUCTION OF NON-SPECIFIC AMPLIFICATION DURING IN VITRO NUCLEIC ACID AMPLIFICATION USING MODIFIED NUCLEIC ACID BASES | F. HOFFMANN-LA-ROCHE AG (CH) | 1992-02-06 | — | — | WO | claimed |